Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience - 04/02/21
, Stefano Piaserico, PhD, MD b, ∗, Luigi Naldi, MD c, d, Paolo Dapavo, MD e, Andrea Conti, MD f, Piergiorgio Malagoli, MD g, Angelo Valerio Marzano, MD h, i, Federico Bardazzi, MD j, Massimo Gasperini, MD k, Simone Cazzaniga, PhD c, d, e, f, g, h, i, j, k, l, Antonio Costanzo, MD m, nand
collaborators in the studies of COVID-19 pandemic‡
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Introduction |
Whether biologic therapies enhance the risk of coronavirus 2019 (COVID-19) or affect the disease outcome in patients with chronic plaque psoriasis remains to be ascertained.
Objective |
We sought to investigate the incidence of hospitalization and death for COVID-19 in a large sample of patients with plaque psoriasis receiving biologic therapies compared with the general population.
Methods |
This is a retrospective multicenter cohort study including patients with chronic plaque psoriasis (n = 6501) being treated with biologic therapy and regularly followed up at the divisions of dermatology of several main hospitals in the Northern Italian cities of Verona, Padua, Vicenza, Modena, Bologna, Piacenza, Turin, and Milan. Incidence rates of hospitalization and death per 10,000 person-months with exact mid-p 95% CIs and standardized incidence ratios were estimated in the patients with psoriasis and compared with those in the general population in the same geographic areas.
Results |
The incidence rate of hospitalization for COVID-19 was 11.7 (95% CI, 7.2-18.1) per 10,000 person-months in patients with psoriasis and 14.4 (95% CI, 14.3-14.5) in the general population; the incidence rate of death from COVID-19 was 1.3 (95% CI, 0.2-4.3) and 4.7 (95% CI, 4.6-4.7) in patients with psoriasis and the general population, respectively. The standardized incidence ratio of hospitalization and death in patients with psoriasis compared with those in the general population was 0.94 (95% CI, 0.57-1.45; P = .82) and 0.42 (95% CI, 0.07-1.38; P = .19), respectively.
Conclusions |
Our data did not show any adverse impact of biologics on COVID-19 outcome in patients with psoriasis. We would not advise biologic discontinuation in patients on treatment since more than 6 months and not infected with severe acute respiratory syndrome coronavirus 2 to prevent hospitalization and death from COVID-19.
Le texte complet de cet article est disponible en PDF.Key words : Psoriasis, biologics, COVID-19, interstitial pneumonia
Abbreviations used : COVID-19, SARS-CoV-2, SIR
Plan
| Supported by Fondazione Cariplo, Fondazione Veronesi, Impact of COVID19 infection on patients affected by inflammatory skin diseases on immuno-suppressive therapies (COVISKIN); ID 1833073 rif. 2020-1363. |
|
| Disclosure of potential conflict of interest: P. Gisondi has been a consultant and/or speaker for Abbvie, Almirall, Amgen, Janssen, LEO Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sandoz, and UCB. S. Piaserico has been a consultant and/or speaker for Abbvie, Almirall, Amgen, Janssen, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, and UCB. L. Naldi has been a consultant and/or speaker for Abbvie, Almirall, Amgen, Janssen, Eli Lilly, and Novartis. P. Dapavo has been a consultant and/or speaker for Abbvie, Amgen-, LEO Pharma, Eli Lilly, Novartis, and UCB. A. Conti has been a consultant and/or speaker for Abbvie, Almirall, Amgen, Eli Lilly, Janssen, LEO Pharma, Novartis, and UCB. P. Malagoli has been a consultant and/or speaker for Abbvie, Almirall, Amgen, Genzyme, Janssen, LEO Pharma, Eli Lilly, Novartis, Sanofi, UCB, and Pierre Fabre. F. Bardazzi has been a consultant and/or speaker for Abbvie, Almirall, Amgen, Janssen, LEO Pharma, Eli Lilly, Novartis, Pfizer, Sandoz, and UCB. A. Costanzo has been a consultant and/or speaker for Abbvie, Almirall, Amgen, Janssen, LEOPharma, Eli Lilly, Novartis, Pfizer, Sandoz, and UCB. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 147 - N° 2
P. 558 - février 2021 Retour au numéro
Article précédent
- Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19
- Carlo Cervia, Jakob Nilsson, Yves Zurbuchen, Alan Valaperti, Jens Schreiner, Aline Wolfensberger, Miro E. Raeber, Sarah Adamo, Sebastian Weigang, Marc Emmenegger, Sara Hasler, Philipp P. Bosshard, Elena De Cecco, Esther Bächli, Alain Rudiger, Melina Stüssi-Helbling, Lars C. Huber, Annelies S. Zinkernagel, Dominik J. Schaer, Adriano Aguzzi, Georg Kochs, Ulrike Held, Elsbeth Probst-Müller, Silvana K. Rampini, Onur Boyman
- Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study
- Giorgio Bozzi, Davide Mangioni, Francesca Minoia, Stefano Aliberti, Giacomo Grasselli, Laura Barbetta, Valeria Castelli, Emanuele Palomba, Laura Alagna, Andrea Lombardi, Riccardo Ungaro, Carlo Agostoni, Marina Baldini, Francesco Blasi, Matteo Cesari, Giorgio Costantino, Anna Ludovica Fracanzani, Nicola Montano, Valter Monzani, Antonio Pesenti, Flora Peyvandi, Marcello Sottocorno, Antonio Muscatello, Giovanni Filocamo, Andrea Gori, Alessandra Bandera
Bienvenue sur EM-consulte, la référence des professionnels de santé.